GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » Cyclically Adjusted PS Ratio

CHRS (Coherus BioSciences) Cyclically Adjusted PS Ratio : 0.22 (As of May. 29, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Cyclically Adjusted PS Ratio?

As of today (2025-05-29), Coherus BioSciences's current share price is $0.8037. Coherus BioSciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $3.70. Coherus BioSciences's Cyclically Adjusted PS Ratio for today is 0.22.

The historical rank and industry rank for Coherus BioSciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

CHRS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.2   Med: 0.58   Max: 2.48
Current: 0.22

During the past years, Coherus BioSciences's highest Cyclically Adjusted PS Ratio was 2.48. The lowest was 0.20. And the median was 0.58.

CHRS's Cyclically Adjusted PS Ratio is ranked better than
95.37% of 497 companies
in the Biotechnology industry
Industry Median: 5.33 vs CHRS: 0.22

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Coherus BioSciences's adjusted revenue per share data for the three months ended in Mar. 2025 was $0.066. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.70 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Coherus BioSciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Coherus BioSciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Cyclically Adjusted PS Ratio Chart

Coherus BioSciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.94 0.38

Coherus BioSciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.48 0.29 0.38 0.22

Competitive Comparison of Coherus BioSciences's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Coherus BioSciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus BioSciences's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Cyclically Adjusted PS Ratio falls into.


;
;

Coherus BioSciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Coherus BioSciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.8037/3.70
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus BioSciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Coherus BioSciences's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.066/134.9266*134.9266
=0.066

Current CPI (Mar. 2025) = 134.9266.

Coherus BioSciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.182 100.684 0.244
201509 0.187 100.392 0.251
201512 0.262 99.792 0.354
201603 0.316 100.470 0.424
201606 0.346 101.688 0.459
201609 3.157 101.861 4.182
201612 0.019 101.863 0.025
201703 0.003 102.862 0.004
201706 0.027 103.349 0.035
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.537 107.251 0.676
201906 1.143 108.070 1.427
201909 1.422 108.329 1.771
201912 1.671 108.420 2.080
202003 1.561 108.902 1.934
202006 1.530 108.767 1.898
202009 1.298 109.815 1.595
202012 1.257 109.897 1.543
202103 1.140 111.754 1.376
202106 1.160 114.631 1.365
202109 1.044 115.734 1.217
202112 0.955 117.630 1.095
202203 0.778 121.301 0.865
202206 0.776 125.017 0.838
202209 0.584 125.227 0.629
202212 0.582 125.222 0.627
202303 0.409 127.348 0.433
202306 0.673 128.729 0.705
202309 0.763 129.860 0.793
202312 0.819 129.419 0.854
202403 0.020 131.776 0.020
202406 0.566 132.554 0.576
202409 0.614 133.029 0.623
202412 0.469 133.157 0.475
202503 0.066 134.927 0.066

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Coherus BioSciences  (NAS:CHRS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Coherus BioSciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
Executives
Dennis M Lanfear director, officer: President and CEO C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell officer: Chief Financial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael officer: See Remarks C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider officer: Chief Commercial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton director 46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler officer: Chief Scientific Officer 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti officer: Chief, Quality & Compliance COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper director 150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson director ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025
Kimberly Jo Tzoumakas director 1170 FAIRFAX STREET, BIRMINGHAM MI 48009